

## REFERENCES

- Ali, N., Rampazzo, R. C. P., Costa, A. D. T., & Krieger, M. A. (2017). Current Nucleic Acid Extraction Methods and Their Implications to Point-of-Care Diagnostics. *BioMed research international*, 2017, 9306564. <https://doi.org/10.1155/2017/9306564>
- Alsayed, S. S. R., & Gunosewoyo, H. (2023). Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. *International journal of molecular sciences*, 24(6), 5202. <https://doi.org/10.3390/ijms24065202>
- Ando, H., Miyoshi-Akiyama, T., Watanabe, S., & Kirikae, T. (2014). A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. *Molecular microbiology*, 91(3), 538–547. <https://doi.org/10.1111/mmi.12476>
- Athanasopoulou, K., Boti, M. A., Adamopoulos, P. G., Skourou, P. C., & Scorilas, A. (2021). Third-Generation Sequencing: The Spearhead towards the Radical Transformation of Modern Genomics. *Life*, 12(1), 30. <https://doi.org/10.3390/life12010030>
- Brammachary, U., Ramachandra, V., Palavesam, S., Raj Cuppusamy Kapalamurthy, V., Muralidhar, A., & Muthaiah, M. (2022). Mechanisms and Action of Drug Resistance on Mycobacterium tuberculosis. *IntechOpen*. <http://dx.doi.org/10.5772/intechopen.108943>.
- Burhan, E., Karyana, M., Karuniawati, A., Kusmiati, T., Wibisono, B. H., Handayani, D., Riyanto, B. S., Sajinadiyasa, I. G. K., Sinaga, B. Y. M., Djaharuddin, I., Indah Sugiyono, R., Susanto, N. H., Diana, A., Kosasih, H., Lokida, D., Siswanto, Neal, A., Lau, C. Y., & Siddiqui, S. (2022). Characteristics of Drug-sensitive and Drug-resistant Tuberculosis Cases among Adults at Tuberculosis Referral Hospitals in Indonesia. *The American journal of tropical medicine and hygiene*, 107(5), 984–991. <https://doi.org/10.4269/ajtmh.22-0142>
- Chaidir, L., Ruesen, C., Dutilh, B. E., Ganiem, A. R., Andryani, A., Apriani, L., Huynen, M. A., Ruslami, R., Hill, P. C., van Crevel, R., & Alisjahbana, B. (2019). Use of whole-genome sequencing to

- predict Mycobacterium tuberculosis drug resistance in Indonesia. *Journal of Global Antimicrobial Resistance*, 16, 170–177. <https://doi.org/10.1016/j.jgar.2018.08.018>
- Chan, W. S., Au, C. H., Chung, Y., Leung, H. C. M., Ho, D. N., Wong, E. Y. L., Lam, T. W., Chan, T. L., Ma, E. S. K., & Tang, B. S. F. (2020). Rapid and economical drug resistance profiling with Nanopore MinION for clinical specimens with low bacillary burden of Mycobacterium tuberculosis. *BMC research notes*, 13(1), 444. <https://doi.org/10.1186/s13104-020-05287-9>
- Delogu, G., Sali, M., & Fadda, G. (2013). The Biology of Mycobacterium tuberculosis Infection. *Mediterranean Journal of Hematology and Infectious Diseases*, 5(1), e2013070. <https://doi.org/10.4084/MJHID.2013.070>
- Dippenaar, A., Goossens, S. N., Grobbelaar, M., Oostvogels, S., Cuypers, B., Laukens, K., Meehan, C. J., Warren, R. M., & van Rie, A. (2022). Nanopore Sequencing for Mycobacterium tuberculosis: a Critical Review of the Literature, New Developments, and Future Opportunities. *Journal of clinical microbiology*, 60(1), e0064621. <https://doi.org/10.1128/JCM.00646-21>
- Faris, A. M., Germossa, G. N., & Beyene, D. T. (2018). Knowledge, Attitude And Practice On Prevention And Control Of Tuberculosis Among Bilida Kebele Residents, Mana Woreda, Jimma Zone, Oromia Region, South West Ethiopia. *Health Science Journal*, 12(5). <https://doi.org/10.21767/1791-809x.1000589>
- Faye, L. M., Hosu, M. C., Oostvogels, S., Dippenaar, A., Warren, R. M., Sineke, N., Vasaikar, S., & Apalata, T. (2023). The Detection of Mutations and Genotyping of Drug-Resistant Mycobacterium tuberculosis Strains Isolated from Patients in the Rural Eastern Cape Province. *Infectious disease reports*, 15(4), 403–416. <https://doi.org/10.3390/idr15040041>
- Fogel, N. (2015). Tuberculosis: A disease without boundaries. *Tuberculosis*, 95(5), 527–531. <https://doi.org/10.1016/j.tube.2015.05.017>
- Getahun, H., Matteelli, A., Abubakar, I., Aziz, M. A., Baddeley, A., Barreira, D., ... & Raviglione, M. (2015). Management of latent Mycobacterium tuberculosis infection: WHO guidelines for

- low tuberculosis burden countries. *European Respiratory Journal*, 46(6), 1563-1576.  
<https://doi.org/10.1183/13993003.01245-2015>
- Gómez-González, P. J., Campino, S., Phelan, J. E., & Clark, T. G. (2022). Portable sequencing of *Mycobacterium tuberculosis* for clinical and epidemiological applications. *Briefings in bioinformatics*, 23(5), bbac256. <https://doi.org/10.1093/bib/bbac256>
- Gopaldaswamy, R., Dusthacker, V. N. A., Kannayan, S., & Subbian, S. (2021). Extrapulmonary Tuberculosis - An Update on the Diagnosis, Treatment and Drug Resistance. *Journal of Respiration*, 1(2), 141-146. <https://doi.org/10.3390/jor1020015>
- Hall, M. B., Rabodoarivelo, M. S., Koch, A., Dippenaar, A., George, S., Grobbelaar, M., Warren, R., Walker, T. M., Cox, H., Gagneux, S., Crook, D., Peto, T., Rakotosamimanana, N., Grandjean Lapierre, S., & Iqbal, Z. (2023). Evaluation of Nanopore sequencing for *Mycobacterium tuberculosis* drug susceptibility testing and outbreak investigation: a genomic analysis. *The Lancet. Microbe*, 4(2), e84–e92. [https://doi.org/10.1016/S2666-5247\(22\)00301-9](https://doi.org/10.1016/S2666-5247(22)00301-9)
- Hoenen, T., Groseth, A., Rosenke, K., Fischer, R. J., Hoenen, A., Judson, S. D., Martellaro, C., Falzarano, D., Marzi, A., Squires, R. B., Wollenberg, K. R., de Wit, E., Prescott, J., Safronetz, D., van Doremalen, N., Bushmaker, T., Feldmann, F., McNally, K., Bolay, F. K., Fields, B., ... Feldmann, H. (2016). Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool. *Emerging infectious diseases*, 22(2), 331–334. <https://doi.org/10.3201/eid2202.151796>
- Idrus, S., & Rosida, L. (2020). Poverty In Indonesia: Critical Review. *Archives of Business Research*, 8(6), 127–132. <https://doi.org/10.14738/abr.86.8326>
- Jacobo-Delgado, Y. M., Rodríguez-Carlos, A., Serrano, C. J., & Rivas-Santiago, B. (2023). *Mycobacterium tuberculosis* cell-wall and antimicrobial peptides: a mission impossible?. *Frontiers in immunology*, 14, 1194923. <https://doi.org/10.3389/fimmu.2023.1194923>
- Jagielski, T., Bakuła, Z., Brzostek, A., Minias, A., Stachowiak, R., Kalita, J., Napiórkowska, A., Augustynowicz-Kopeć, E., Żaczek, A., Vasiliauskiene, E., Bielecki, J., & Dziadek, J. (2018). Characterization of Mutations Conferring Resistance to Rifampin in *Mycobacterium*

- tuberculosis Clinical Strains. *Antimicrobial agents and chemotherapy*, 62(10), e01093-18.  
<https://doi.org/10.1128/AAC.01093-18>
- Jang, J. G., & Chung, J. H. (2020). Diagnosis and treatment of multidrug-resistant tuberculosis. *Yeungnam University journal of medicine*, 37(4), 277–285.  
<https://doi.org/10.12701/yujm.2020.00626>
- Kabir, S., Tahir, Z., Mukhtar, N., Sohail, M., Saqalein, M., & Rehman, A. (2020). Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. *BMC pulmonary medicine*, 20(1), 138. <https://doi.org/10.1186/s12890-020-1172-4>
- Kafetzopoulou, L. E., Pullan, S. T., Lemey, P., Suchard, M. A., Ehichioya, D. U., Pahlmann, M., Thielebein, A., Hinzmann, J., Oestereich, L., Wozniak, D. M., Efthymiadis, K., Schachten, D., Koenig, F., Matjeschk, J., Lorenzen, S., Lumley, S., Ighodalo, Y., Adomeh, D. I., Olorok, T., Omomoh, E., ... Duraffour, S. (2019). Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. *Science (New York, N.Y.)*, 363(6422), 74–77.  
<https://doi.org/10.1126/science.aau9343>
- Kalscheuer, R., Palacios, A., Anso, I., Cifuentes, J., Anguita, J., Jacobs, W. R., Jr, Guerin, M. E., & Prados-Rosales, R. (2019). The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis. *The Biochemical journal*, 476(14), 1995–2016.  
<https://doi.org/10.1042/BCJ20190324>
- Kaso, A. W., & Hailu, A. (2021). Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia. *PloS one*, 16(10), e0259056. <https://doi.org/10.1371/journal.pone.0259056>
- Lawn, S. D., & Nicol, M. P. (2011). Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. *Future microbiology*, 6(9), 1067–1082. <https://doi.org/10.2217/fmb.11.84>

- Lee, H. Y., Gurtowski, J., Yoo, S. J., Nattestad, M., Marcus, S., Goodwin, S., McCombie, W. R., & Schatz, M. C. (2016). Third-generation sequencing and the future of genomics. *bioRxiv*, 048603. <https://doi.org/10.1101/048603>
- Lestari, B. W., Nijman, G., Larasmanah, A., Soeroto, A. Y., Santoso, P., Alisjahbana, B., Chaidir, L., Andriyoko, B., van Crevel, R., & Hill, P. C. (2023). Management of drug-resistant tuberculosis in Indonesia: a four-year cascade of care analysis. *The Lancet Regional Health - Southeast Asia*, 100294. <https://doi.org/10.1016/j.lansea.2023.100294>
- Loman, N. J., Quick, J., & Simpson, J. T. (2015). A complete bacterial genome assembled de novo using only nanopore sequencing data. *Nature methods*, 12(8), 733–735. <https://doi.org/10.1038/nmeth.3444>
- Luies, L., & du Preez, I. (2020). The Echo of Pulmonary Tuberculosis: Mechanisms of Clinical Symptoms and Other Disease-Induced Systemic Complications. *Clinical microbiology reviews*, 33(4), e00036-20. <https://doi.org/10.1128/CMR.00036-20>
- Magdy, T., Kuo, H. H., & BurrIDGE, P. W. (2020). Precise and Cost-Effective Nanopore Sequencing for Post-GWAS Fine-Mapping and Causal Variant Identification. *iScience*, 23(4), 100971. <https://doi.org/10.1016/j.isci.2020.100971>
- Mahomed, S., Mlisana, K., Cele, L., & Naidoo, K. (2020). Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: Impact on bedside clinical decision making. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 20, 100176. <https://doi.org/10.1016/j.jctube.2020.100176>
- Maladan, Y., Krismawati, H., Wahyuni, T., Tanjung, R., Awaludin, K., Audah, K. A., & Parikesit, A. A. (2021). The whole-genome sequencing in predicting Mycobacterium tuberculosis drug susceptibility and resistance in Papua, Indonesia. *BMC genomics*, 22(1), 844. <https://doi.org/10.1186/s12864-021-08139-3>
- Musser J. M. (1995). Antimicrobial agent resistance in mycobacteria: molecular genetic insights. *Clinical microbiology reviews*, 8(4), 496–514. <https://doi.org/10.1128/CMR.8.4.496>

- Noviyani, A., Nopsopon, T., & Pongpirul, K. (2021). Variation of Tuberculosis Prevalence Across Diagnostic Approaches and Geographical Areas of Indonesia. *PLoS ONE*, *16*(10), e0258809. <https://doi.org/10.1371/journal.pone.0258809>
- O'Connor, C., & Brady, M. F. (2022). *Isoniazid - LiverTox - NCBI Bookshelf*. National Library of Medicine. <https://www.ncbi.nlm.nih.gov/books/NBK548754/>
- Oxford Nanopore Technologies. (2021). *How nanopore sequencing works*. Oxford Nanopore Technologies. <https://nanoporetech.com/platform/technology>
- Pearlman, S. I., Leelawong, M., Richardson, K. A., Adams, N. M., Russ, P. K., Pask, M. E., Wolfe, A. E., Wessely, C., & Haselton, F. R. (2020). Low-Resource Nucleic Acid Extraction Method Enabled by High-Gradient Magnetic Separation. *ACS applied materials & interfaces*, *12*(11), 12457–12467. <https://doi.org/10.1021/acsami.9b21564>
- Phelan, J. E., Lim, D. R., Mitarai, S., de Sessions, P. F., Tujan, M. A. A., Reyes, L. T., Medado, I. A. P., Palparan, A. G., Naim, A. N. M., Jie, S., Segubre-Mercado, E., Simoes, B., Campino, S., Hafalla, J. C., Murase, Y., Morishige, Y., Hibberd, M. L., Kato, S., Ama, M. C. G., & Clark, T. G. (2019). Mycobacterium tuberculosis whole genome sequencing provides insights into the Manila strain and drug-resistance mutations in the Philippines. *Scientific reports*, *9*(1), 9305. <https://doi.org/10.1038/s41598-019-45566-5>
- Piton, J., Petrella, S., Delarue, M., André-Leroux, G., Jarlier, V., Aubry, A., & Mayer, C. (2010). Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. *PloS one*, *5*(8), e12245. <https://doi.org/10.1371/journal.pone.0012245>
- Puspita, T., Suryatma, A., Simarmata, O. S., Veridona, G., Lestary, H., Athena, A., Pambudi, I., Sulistyono, S., & Pakasi, T. T. (2021). Spatial variation of tuberculosis risk in Indonesia 2010-2019. *Health Science Journal of Indonesia*, *12*(2), 104–110. <https://doi.org/10.22435/hsji.v12i2.5467>
- Safi, H., Sayers, B., Hazbón, M. H., & Alland, D. (2008). Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid,

and rifampin. *Antimicrobial agents and chemotherapy*, 52(6), 2027–2034.  
<https://doi.org/10.1128/AAC.01486-07>

Safi, H., Lingaraju, S., Amin, A., Kim, S., Jones, M., Holmes, M., McNeil, M., Peterson, S. N., Chatterjee, D., Fleischmann, R., & Alland, D. (2013). Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl- $\beta$ -D-arabinose biosynthetic and utilization pathway genes. *Nature genetics*, 45(10), 1190–1197.  
<https://doi.org/10.1038/ng.2743>

Schatz M. C. (2017). Nanopore sequencing meets epigenetics. *Nature methods*, 14(4), 347–348.  
<https://doi.org/10.1038/nmeth.4240>

Seung, K. J., Keshavjee, S., & Rich, M. L. (2015). Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. *Cold Spring Harbor perspectives in medicine*, 5(9), a017863.  
<https://doi.org/10.1101/cshperspect.a017863>

Soeroto, A. Y., Lestari, B. W., Santoso, P., Chaidir, L., Andriyoko, B., Alisjahbana, B., van Crevel, R., & Hill, P. C. (2019). Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. *PLoS one*, 14(2), e0213017.  
<https://doi.org/10.1371/journal.pone.0213017>

Sotgiu, G., Centis, R., D'ambrosio, L., & Migliori, G. B. (2015). Tuberculosis treatment and drug regimens. *Cold Spring Harbor perspectives in medicine*, 5(5), a017822.  
<https://doi.org/10.1101/cshperspect.a017822>

Sulistijawati, R. S., Icksan, A. G., Lolong, D. B., & Nurwidya, F. (2019). Thoracic Radiography Characteristics of Drug Sensitive Tuberculosis and Multi Drug Resistant Tuberculosis: A Study of Indonesian National Tuberculosis Prevalence Survey. *Acta medica (Hradec Kralove)*, 62(1), 24–29. <https://doi.org/10.14712/18059694.2019.42>

Sultana, Z. Z., Hoque, F. U., Beyene, J., Akhlak-UI-Islam, M., Khan, M. H. R., Ahmed, S., Hawlader, D. H., & Hossain, A. (2021). HIV infection and multidrug resistant tuberculosis: a systematic

review and meta-analysis. *BMC infectious diseases*, 21(1), 51.  
<https://doi.org/10.1186/s12879-020-05749-2>

Surendra, H., Elyazar, I. R. F., Puspaningrum, E., Darmawan, D., Pakasi, T. T., Lukitosari, E., Sulisty, S., Deviernur, S. M., Fuady, A., Thwaites, G., van Crevel, R., Shankar, A. H., Baird, J. K., & Hamers, R. L. (2023). Impact of the COVID-19 pandemic on tuberculosis control in Indonesia: a nationwide longitudinal analysis of programme data. *The Lancet. Global health*, 11(9), e1412–e1421. [https://doi.org/10.1016/S2214-109X\(23\)00312-1](https://doi.org/10.1016/S2214-109X(23)00312-1)

Tafess, K., Ng, T. T. L., Lao, H. Y., Leung, K. S. S., Tam, K. K. G., Rajwani, R., Tam, S. T. Y., Ho, L. P. K., Chu, C. M. K., Gonzalez, D., Sayada, C., Ma, O. C. K., Nega, B. H., Ameni, G., Yam, W. C., & Siu, G. K. H. (2020). Targeted-Sequencing Workflows for Comprehensive Drug Resistance Profiling of Mycobacterium tuberculosis Cultures Using Two Commercial Sequencing Platforms: Comparison of Analytical and Diagnostic Performance, Turnaround Time, and Cost. *Clinical chemistry*, 66(6), 809–820. <https://doi.org/10.1093/clinchem/hvaa092>

Tam, K. K., Leung, K. S., Siu, G. K., Chang, K. C., Wong, S. S., Ho, P. L., Leung, E. K., & Yam, W. C. (2019). Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing. *Journal of clinical microbiology*, 57(8), e00145-19. <https://doi.org/10.1128/JCM.00145-19>

Tania, T., Soedarmono, P., Kusumawati, R. L., Rukmana, A., Pratama, W. A., Regmi, S. M., Kaewprasert, O., Chaiprasert, A., Chongsuvivatwong, V., & Faksri, K. (2020). Whole-genome sequencing analysis of multidrug-resistant Mycobacterium tuberculosis from Java, Indonesia. *Journal of Medical Microbiology*, 69(7), 1013–1019. <https://doi.org/10.1099/jmm.0.001221>

Tseng, S. T., Tai, C. H., Li, C. R., Lin, C. F., & Shi, Z. Y. (2015). The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan. *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi*, 48(3), 249–255. <https://doi.org/10.1016/j.jmii.2013.08.018>



- Tiberi, S., Utjesanovic, N., Galvin, J., Centis, R., D'Ambrosio, L., van den Boom, M., Zumla, A., & Migliori, G. B. (2022). Drug resistant TB - latest developments in epidemiology, diagnostics and management. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases*, *124 Suppl 1*, S20–S25. <https://doi.org/10.1016/j.ijid.2022.03.026>
- Vilchèze, C., & Jacobs, W. R., Jr (2014). Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. *Microbiology spectrum*, *2*(4), MGM2–2013. <https://doi.org/10.1128/microbiolspec.MGM2-0014-2013>
- Willby, M., Sikes, R. D., Malik, S., Metchock, B., & Posey, J. E. (2015). Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. *Antimicrobial agents and chemotherapy*, *59*(9), 5427–5434. <https://doi.org/10.1128/AAC.00662-15>
- World Health Organization. (2020). *Global Tuberculosis Report 2020*. Geneva: WHO
- World Health Organization. (2022). *Global Tuberculosis Report 2022*. Geneva: WHO
- Xi, Y., Zhang, W., Qiao, R. J., & Tang, J. (2022). Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. *PloS one*, *17*(6), e0270003. <https://doi.org/10.1371/journal.pone.0270003>
- Xiao, T., & Zhou, W. (2020). The third generation sequencing: the advanced approach to genetic diseases. *Translational pediatrics*, *9*(2), 163–173. <https://doi.org/10.21037/tp.2020.03.06>
- Zhang, Q., An, X., Liu, H., Wang, S., Xiao, T., & Liu, H. (2019). Uncovering the Resistance Mechanism of Mycobacterium tuberculosis to Rifampicin Due to RNA Polymerase H451D/Y/R Mutations From Computational Perspective. *Frontiers in chemistry*, *7*, 819. <https://doi.org/10.3389/fchem.2019.00819>
- Zhao, K., Tu, C., Chen, W., Liang, H., Zhang, W., Wang, Y., Jin, Y., Hu, J., Sun, Y., Xu, J., & Yu, Y. (2022). Rapid Identification of Drug-Resistant Tuberculosis Genes Using Direct PCR Amplification and Oxford Nanopore Technology Sequencing. *The Canadian journal of infectious diseases &*

*medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie  
medicale, 2022, 7588033. <https://doi.org/10.1155/2022/7588033>*